Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus

Yoshihiko Saito(National Archives and Records Administration), Takeshi Morimoto(Hyogo Medical University), Hisao Ogawa(Kumamoto University Hospital), Izuru Masuda(Takeda (Japan)), Sadanori Okada(Hyogo Medical University), Hideaki Jinnouchi, Masako Waki(Shizuoka City Hospital), Masafumi Nakayama(Kumamoto University), Mio Sakuma(Hyogo Medical University), Naofumi Doi(Nara Medical University), Hirofumi Soejima(Kumamoto Health Science University)
Circulation
November 16, 2016
10.1161/circulationaha.116.025760
Cited by 141

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
|JAMA|2019|830
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753